[2] [2] Badmus OO, Hillhouse SA, Anderson CD, et al. Molecular mechanisms of metabolic associated fatty liver disease (MAFLD): functional analysis of lipid metabolism pathways[J]. Clin Sci (Lond), 2022, 136(18): 1347-1366.

[3] [3] Wang JQ, Li LL, Hu A, et al. Inhibition of ASGR1 decreases lipid levels by promoting cholesterol excretion[J]. Nature, 2022, 608(7922): 413-420.

[7] [7] He YM, Chen XB, Li YC, et al. Curcumin supplementation alleviates hepatic fat content associated with modulation of gut microbiota-dependent bile acid metabolism in patients with nonalcoholic simple fatty liver disease: a randomized controlled trial[J]. Am J Clin Nutr, 2024, 120(1): 66-79.

[8] [8] Prud'homme GJ, Kurt M, Wang QH. Pathobiology of the klotho antiaging protein and therapeutic considerations[J]. Front Aging, 2022, 3: 931331.

[11] [11] Peng Y, Ao MY, Dong BH, et al. Anti-inflammatory effects of curcumin in the inflammatory diseases: status, limitations and countermeasures[J]. Drug Des Devel Ther, 2021, 15: 4503-4525.

[12] [12] Zhu YY, Huang XL, Deng ZC, et al. Orally biomimetic metal-phenolic nanozyme with quadruple safeguards for intestinal homeostasis to ameliorate ulcerative colitis[J]. J Nanobiotechnology, 2024, 22(1): 545.

[13] [13] Lee ES, Kwon MH, Kim HM, et al. Curcumin analog CUR5-8 ameliorates nonalcoholic fatty liver disease in mice with high-fat diet-induced obesity[J]. Metabolism, 2020, 103: 154015.

[14] [14] Chen XH, Liang JJ, Bin WG, et al. Anti-hyperlipidemic, anti-inflammatory, and ameliorative effects of DRP1 inhibition in rats with experimentally induced myocardial infarction[J]. Cardiovasc Toxicol, 2021, 21(12): 1000-1011.

[15] [15] Shaito A, Aramouni K, Assaf R, et al. Oxidative stress-induced endothelial dysfunction in cardiovascular diseases[J]. Front Biosci (Landmark Ed), 2022, 27(3): 105.

[16] [16] Labban RSM, Alfawaz HA, Almnaizel AT, et al. Garcinia mangostana extract and curcumin ameliorate oxidative stress, dyslipidemia, and hyperglycemia in high fat diet-induced obese Wistar albino rats[J]. Sci Rep, 2021, 11(1): 7278.

[17] [17] Zhang JX, Zhang WX, Yang L, et al. Phytochemical gallic acid alleviates nonalcoholic fatty liver disease via AMPK-ACC-PPAR axis through dual regulation of lipid metabolism and mitochondrial function[J]. Phytomedicine, 2023, 109: 154589.

[18] [18] Lee JH, Kim DH, Kim M, et al. Mitochondrial ROS-mediated metabolic and cytotoxic effects of isoproterenol on cardiomyocytes are p53-dependent and reversed by curcumin[J]. Molecules, 2022, 27(4): 1346.

[19] [19] Sharma S, Sharma D, Dhobi M, et al. An insight to treat cardiovascular diseases through phytochemicals targeting PPAR-[J]. Mol Cell Biochem, 2024, 479(3): 707-732.

[20] [20] Francis MR, El-Sheakh AR, Suddek GM. Saroglitazar, a dual PPAR-/ agonist, alleviates LPS-induced hepatic and renal injury in rats[J]. Int Immunopharmacol, 2023, 115: 109688.